Solar power plant EPC small molecule drugs for innovation ShangLing pharmaceutical finished tens of millions of dollars to A round of funding

On April 17, the investment community news, photovoltaic (pv) grid, small molecule drug research and development, innovation & other; Lenk pharmaceutical & throughout; Announced it had completed before the Spring Festival this year tens of millions of dollars to A round of funding, led by DE cheng capital, solar equipment, zheshang and innovation, the original investor power Fang Zi Ben and cantechs capital continue to vote.

it is understood that this round of financing will be mainly used to promote lenk pharmaceutical research and development pipeline in multiple clinical purpose IND application referred to in the preceding paragraph and 2-3 phase I clinical trials. In addition the company also will use the raised funds to promote the development of new projects and international cooperation.

lenk pharmaceutical is a focus on cancer and autoimmune disease of small molecule drug research and development of biological pharmaceutical innovation enterprise, the main focus, immune and inflammatory diseases such as tumor, solar power network, through their own research and development, the overseas big drug firms technology authorized import and output, and a variety of forms such as cooperative development, the development of new drug projects. In March 2018, lenk pharmaceutical had finished millions dollars angel round, led by cantechs capital, power Fang Zi, its capital, and investment.

lenk pharmaceutical, chairman and chief executive of Dr Wan Zhaokui said: & other; The reason we can get the trust and support of many famous investment institutions, is because we have the honor to gather the industry of new drug innovation experience and with global vision scientists and management personnel. Although we are based in hangzhou, but the research and development of new drug innovation lenk positioning in the international market as the ultimate goal. We will integrate resources, enrich the existing research pipelines at the same time to speed up the innovation medicine clinical development. We are guided by the demands of clinical, solar portal, actively carry out international academic and industrial cooperation, for the purpose of saving lives, do everything we can for the welfare of the patient as soon as possible! ”

cantechs Jin Qi said, executive director of capital & other; There is a huge tumor and inflammation/immune field is not meet the medical needs. Cantechs capital based on is not meet medical demand, as well as the value investment idea, investment lenk pharmaceutical industry. Cantechs capital will continue to be in is not meet the medical needs of direction finding potential solutions and excellent business team, trying to make life more healthy and happy. ”

and solar energy